Buscador de publicacions

Publicacions

  • Monterrubio C, Paco-Mercader S, Vilà-Ubach M, Rodriguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J and Carcaboso AM.

    Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts

    PHARMACEUTICAL RESEARCH . 32(9): 2889-2900. Nº de cites: 10

    [doi:10.1007/s11095-015-1671-9]

  • Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, Del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pastó G, San-Segundo L, Vilà-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J and de Álava E.

    The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

    Oncotarget . 6(22): 18875-18890. Nº de cites: 64

    [doi:10.18632/oncotarget.4303]

  • Mora J, Cruz-Martínez O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador-Hernandez H, Suñol M, Carrasco-Torrents R, Guillen-Quesada A, Mañé S and de Torres C.

    Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 17(7): 521-529. Nº de cites: 12

    [doi:10.1007/s12094-014-1273-8]

  • Brosa M, García Del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Luaces-Cubells C and Montoto C.

    Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma

    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH . 15(2): 331-340. Nº de cites: 8

    [doi:10.1586/14737167.2015.972378]

  • Puerta P, Guillen-Quesada A, Mora J, Suñol M and Ferrer E.

    Isolated skull metastasis of Ewing's Sarcoma in a child

    Austin Journal of Cancer and Clinical Research . 2(5): 1046.

  • Mora J, Modak S, Cheung NK, Meyers P, de Alava E, Kushner B, Magnan H, Tirado OM, Laquaglia M, Ladanyi M and Rosai J.

    Desmoplastic small round cell tumor 20 years after its discovery

    FUTURE ONCOLOGY . 11(7): 1071-1081. Nº de cites: 33

    [doi:10.2217/fon.15.32]

  • Gomez-Gonzalez S, Castellano G, Mayol G, Suñol M, Queiros A, Bibikova M, Nazor KL, Loring JF, Lemos I, Rodríguez E, de Torres C, Mora J, Martín-Subero JI and Lavarino C.

    DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights

    EPIGENOMICS . 7(7): 1137-1153. Nº de cites: 36

    [doi:10.2217/epi.15.49]

  • Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, Ambrogio L, Sougnez C, Sivachenko A, Walensky LD, Wagle N, Mora J, de Torres C, Lavarino C, Dos Santos Aguiar S, Yunes JA, Brandalise SR, Mercado-Celis GE, Melendez-Zajgla J, Cárdenas-Cardós R, Velasco-Hidalgo L, Roberts CW, Garraway LA, Rodriguez-Galindo C, Gabriel SB, Lander ES, Golub TR, Orkin SH, Getz G and Janeway KA.

    Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 111(51): 5564-5573. Nº de cites: 324

    [doi:10.1073/pnas.1419260111]

  • Marques Howarth M, Simpson D, Ngok SP, Nieves B, Chen R, Siprashvili Z, Vaka D, Breese MR, Crompton BD, Alexe G, Hawkins DS, Jacobson D, Brunner AL, West R, Mora J, Stegmaier K, Khavari P and Sweet-Cordero EA.

    Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis

    JOURNAL OF CLINICAL INVESTIGATION . 124(12): 5275-5290. Nº de cites: 81

    [doi:10.1172/JCI72124]

  • Jové M, Mora J, Sanjuan X, Rodriguez E, Robledo M, Farran L and Garcia del Muro X.

    Simultaneous KIT mutation and succinate dehydrogenase (SDH) deficiency in a patient with a gastrointestinal stromal tumour and Carney-Stratakis syndrome: a case report

    Histopathology . 65(5): 712-717. Nº de cites: 7

    [doi:10.1111/his.12506]